Abstract: A dermal patch is provided which includes a substrate formed of a hydrophobic and hydrophilic fiber mixture, and a hydrogel adhesive deposited onto the substrate. The adhesive contains an alpha or beta hydroxy acid. The patch is applied to skin for treating the signs of aging, especially around areas of the eye.

Abstract: An aerosol pharmaceutical formulation for pulmonary and nasal delivery is provided. The formulation comprises a pharmaceutical agent, water, a phenol and a propellant. Optionally, an excipient such as glycerin or polyglycerin, lysine or polylysine, or other salts, flavoring or coloring agents, protease inhibitors or stabilizers can be added. A method of administering the formulation with a metered dose dispenser, and a dispenser containing the formulation are also provided.

Abstract: A mixed liposome pharmaceutical formulation with multilamellar vesicles is provided. The formulation comprises a pharmaceutical agent, water, an alkali metal alkyl sulfate, at least one membrane mimetic amphiphile, and at least one phospholipid. When aerosol delivery is intended, the formulation also comprises a propellant and a phenol. A metered dose dispenser containing the formulation, as well as a method of administering the formulation, are also provided.

Abstract: The invention provides an aqueous hair styling aid comprising a volatile silicone selected from cyclic silicones having the general formula (I): [(CH3)2Si—O—]n  (I) wherein n=3-7, and short chain linear silicones having the general formula (II): (CH3)3Si—O—[Si(CH3)2O]nSi(CH3)3  (II) wherein n=1-7; together with hairstyling polymer, surfactant and at least 5% water.

Abstract: Provided is a solution aerosol formulation adapted for use in a pressurized aerosol container. The aerosol formulation is formulated from a composition containing Budesonide, at least one fluoroalkane propellant, and a cosolvent present in an amount that dissolves or solubilizes the Budesonide in the mixture of cosolvent and propellant.

Abstract: Web materials which have two or more skin care compositions disposed thereon. The skin care compositions are transferable to the wearer's skin by normal contact and/or wearer motion and/or body heat. The skin care compositions disclosed in the present invention are selected to maintain and/or improve the skin health of the wearer upon transfer during use, for example, to provide a skin protective barrier or a therapeutic benefit; to minimize the abrasion between the cuffs and skin in the area where the cuffs contact the wearer's skin, resulting in less skin irritation; to improve BM clean up on the skin, or to improve the barrier properties of the cuffs. Web materials of the present invention have a wide range of potential uses in both durable and disposable articles, but are particularly well suited for use in disposable absorbent articles such as disposable diapers, incontinent briefs, training pants, sanitary napkins, and the like.

Abstract: A homogeneous steroid-containing preformulation for production of solid and semi-solid pharmaceutical preparations containing a uniform constant dosage of at least one steroid in a range from 0.001 to 1 percent by weight is described. This steroid-containing preformulation contains of from 0.001 to 50 percent by weight of the at least one steroid. The homogeneous steroid-containing preformulation is made by a method including dissolving the at least one steroid in a solvent to form a dispersant; dispersing an adjuvant consisting of adjuvant particles in the dispersant in a mass ratio of the adjuvant to the at least one steroid of 1:1 to 1000:1 to form a suspension; and creating a spray-mist of the suspension so as to evaporate and remove the solvent from the suspension and thus to form a dried particulate which includes steroid-containing particles. The droplets in the spray mist have a droplet diameter greater than a mean diameter of the adjuvant particles.

Abstract: A solution or gel composition containing activated chlorine dioxide and phosphates, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for treating herpes virus. The preferred concentration ranges are between about 0.005% to about 2.0% chlorine dioxide, and between about 0.02% to about 3.0% of a phosphate compound. The phosphate compound retards escape of chlorine dioxide in the pH range of 6.0 to 7.4, at which pH chlorine dioxide becomes activated and releases sufficient chlorine dioxide to reduce motility and become lethal to the involved micro-organisms.

Abstract: Foaming propellant compositions for use in hair mousse compositions described. These compositions contain hydrofluorocarbon 152A and a suitable hydrocarbon in a ratio of about 30 to 70; to about 50 to 50; more preferably about 40 to 60. These compositions comprise the hydrofluorocarbon 152A; and a hydrocarbon, selected from the group consisting of propane, isobutane, and n-butane in the above recited ratios. The above propellant mixture is about 4 to 9 wt. % of total foaming, hair care composition.

Abstract: A pharmaceutical formulation for administration by inhalation, a micronized active compound or micronized active compound mixture with a mean particle size of 0.1 &mgr;m to 10 &mgr;m being applied to a pharmaceutically acceptable excipient having a mean particle size of 200 &mgr;m to 1000 &mgr;m without the use of binders.

Abstract: An aerosol product comprising the following compound (A), a middle-chain fatty acid triglyceride and a liquefied hydrofluoroalkane is provided. In the production of an aerosol product using a liquefied hydrofluoroalkane as propellant, the use of a middle-chain fatty acid triglyceride as dispersant insures good dispersion of compound (A) in the propellant. The result is an aerosol product free from variation in the dispensed dose of compound (A).

Abstract: A method and solution or gel topical preparation containing chlorine dioxide and a phosphate compound, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for treating itching of the vagina. The preferred concentration ranges are between about 0.005% to about 2.0% chlorine dioxide, and between about 0.02% to about 3.0% phosphate compound. The phosphate compound retards escape of chlorine dioxide in the pH range of about 6.0 to 7.4, at which pH chlorine dioxide becomes activated and releases sufficient chlorine dioxide to reduce motility and become lethal to the involved micro-organisms.

Abstract: Assembly for the distribution of a pharmaceutical solution, contained in multi-dose vial, into single-dose carpules for single use, comprising single-dose carpules and a distribution apparatus, in which assembly pressure and suction means are provided to circulate a liquid from the carpules to the vial and from the vial to the carpules, by means of a network of channels.

Abstract: A solution or gel composition containing activated chlorine dioxide and a phosphate compound, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for treating a Chlamydia infection. The preferred concentration ranges are between about 0.005% to about 2.0% chlorine dioxide, and between about 0.02% to about 3.0% phosphate compound. The phosphate compound retards escape of chlorine dioxide in the pH range of 6.0 to 7.4, at which pH the chlorine dioxide becomes activated and releases sufficient chlorine dioxide to reduce motility and become lethal to the involved micro-organisms.

Abstract: A composition for treatment of bacterial infections of burns and wounds of the skin comprises an effective amount of at least one lytic enzyme produced by a bacteria infected with a bacteriophage specific for said bacteria, and a carrier for delivering said at least one lytic enzyme to the skin. The carrier may be, but is not limited to, a liquid solution applied to a bandage.

Abstract: A granulated composition for bleaching hair compresses granules of a pulverulent material which is sodium persulfate, potassium persulfate, ammonium persulfate, sodium perborate, potassium perborate, ammonium perborate, barium peroxide, strontium peroxide and mixtures thereof bound together with propylene glycol having a molecular weight ranging from 200 to 10,000. The binder is present in an amount not exceeding 25 percent by weight of the composition.

Abstract: A method and solution or gel composition containing activated chlorine dioxide and phosphates, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for lubricating the vagina and for treating HIV. The preferred concentration ranges are between about 0.005% to about 2.0% chlorine dioxide, and between about 0.02% to about 3.0% phosphate. The phosphate compound retards escape of chlorine dioxide in the pH range of about 6.0 to 7.4, at which pH the chlorine dioxide becomes activated and releases sufficient chlorine dioxide to reduce motility and become lethal to the involved micro-organisms.

Abstract: An absorbent wound filler having high capacity for absorbing wound exudate comprising a polymeric matrix having absorbing powders dispersed within the matrix and method of treating an exudating wound by applying the wound filler to the wound. The absorbing powders contain sodium calcium alginates and also may contain cross-linked sodium carboxymethylcellulose, absorbent polyacrylates and water soluble hydrocolloids.

Abstract: A fluid delivery system and a propellant therefor. The propellant comprises a mixture of a plurality of substances, the precise by-weight or by-molar combination of which is used to set the propellant pressure within a desirable pressure range. At least one of the plurality of propellant substances is a relatively higher vapor pressure fluid; and at least one of the plurality of propellant substances is a relatively lower vapor pressure fluid.

Abstract: The present invention discloses a method and composition for the treatment of bacterial infections by the parenteral introduction of at least one lytic enzyme produced by a bacteria infected with a bacteriophage specific for that bacteria and an appropriate carrier for delivering the lytic enzyme into a patient. The injection can be done intramuscularly, subcutaneously, or intravenously.